What Emerging Technology Partners does

Emerging Technology Partners (ETP Capital) is a privately-held life sciences venture capital firm founded in 2000 by Dr. Wei-Wu He and headquartered at 425 Eccles Avenue in South San Francisco, California. The firm invests across the full life sciences funding spectrum from seed stage through post-IPO rounds, acting as lead investor or syndicate partner, and is explicitly structured for cross-border US-China deal activity with investment partners in San Francisco, Boston, Washington DC, and Beijing. The firm's stated mission is to provide capital and management assistance to build and commercialize breakthrough diagnostic and therapeutic products in life sciences while delivering returns to investors.

The platform supports portfolio companies beyond capital, including strategic alliance facilitation, cross-border partnership development, management recruitment, and product or technology acquisition, positioning ETP as an operating-oriented specialist investor rather than a passive financial backer. Its disclosed portfolio spans precision oncology (Genetron Health), longevity and precision medicine (Human Longevity Inc.), biopharmaceuticals (CASI Pharmaceuticals, MacroGenics, Dynavax, Ziopharm, Applied Therapeutics, X4 Pharmaceuticals, GAIN Therapeutics), molecular biology and genomics (OriGene Technologies, HTG Molecular, BioNano Genomics, EdiGene, TCR² Therapeutics, Seventh Sense Biosystems), immunology (NexImmune, Cellestia), and digital health (Deep Longevity, Edifice Health, Sleep Score Labs, BlueJay Health, Doctors for Me). Founder Dr. Wei-Wu He sits as Executive Chairman of Human Longevity Inc. and Chairman of OriGene Technologies, embedding ETP leadership into portfolio governance.

ETP generates returns through equity investments in portfolio companies rather than product or service revenue; revenue mechanics consist of standard venture fund management fees and carried interest on successful exits, with investment terms negotiated individually. Go-to-market is direct, with deal flow sourced through the firm's industry network, scientific and clinical connections, and direct outreach to founders. The firm operates as a Delaware/California LLC with a regional entity (ETP China, est. 2017) and currently employs between 11 and 50 professionals.

Name

Emerging Technology Partners

Legal name

Emerging Technology Partners, LLC

Website

https://etpvc.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Emerging Technology Partners is a privately-held life sciences venture capital firm founded in 2000, investing from seed through post-IPO stages with a US-China cross-border focus. It backs biotech, precision oncology, longevity, and digital health companies, providing capital plus management recruitment and strategic partnership support.

Ownership category

akta.pro rank

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Venture Capital Returns: ETP Capital generates returns through equity investments in life sciences companies. The fund provides capital to portfolio companies and assists in building and commercializing breakthrough diagnostic and therapeutic products, seeking superior returns for investors through successful exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Emerging Technology Partners (ETP Capital) is a life sciences-focused venture capital firm that finds, invests in, and builds innovative biomedical companies from seed stage through post-IPO rounds. The firm provides equity capital and actively supports portfolio companies by facilitating strategic alliances, cross-border partnerships, management recruitment, and product/technology acquisitions to accelerate growth in the US and China markets.

Product overview

Emerging Technology Partners (ETP Capital) is a life sciences-focused venture capital firm established in 2000 with cross-border investment operations spanning San Francisco, Boston, Washington DC, and Beijing. ETP operates as a unified investment platform offering venture and growth capital financing from seed stage through post-IPO rounds. The firm supports portfolio companies through strategic alliances, cross-border partnerships, management recruitment, and technology acquisition. ETP China, established in 2017, extends the same mission to bring biomedical innovations to the world through the China market. The portfolio encompasses over 30 companies across precision oncology, longevity care, molecular diagnostics, immunology, and digital health sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• ETP Capital A life sciences-focused investment fund providing capital and management assistance to build and commercialize breakthrough diagnostic and therapeutic products in life sciences.
• Venture & Growth Investment Equity investment offering covering seed through post-IPO rounds, comfortable acting as lead investor or partner in syndicated rounds where key success elements are in place.
• ETP China China-focused subsidiary established in 2017 to extend ETP's life sciences investment mission and cross-border partnership capabilities into the China market.

Quantifiable outcome

• Over 60 biotech companies funded throughout career
• +1 more outcomes

Named customers4 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• OrbiMed: One of the largest dedicated healthcare and life sciences venture capital firms, investing across stages from seed to growth. Directly comparable as a specialist life sciences investor serving biotech founders with capital and operating support.
• RA Capital Management: Boston-based, life sciences-focused investment firm with crossover and public-equity capabilities alongside private venture. Comparable as a sector-specialist biotech investor with deep scientific due diligence and stage-flexible capital.
• Atlas Venture: Early-stage life sciences venture firm building biotech companies from inception. Comparable as a specialist biotech investor focused on drug development and platform technologies addressing unmet clinical needs.
• ARCH Venture Partners: Long-tenured venture firm (founded 1986) investing in deep tech and life sciences from seed through growth. Comparable as a founder-led, science-driven biotech investor with multi-stage capability and significant biotech exits.
• SV Health Investors: Boston and London-based venture and growth investor focused on biotech and medtech. Comparable as a sector-specialist life sciences firm with transatlantic reach and stage-flexible deployment.
• Flagship Pioneering: Biotech creation engine originating and developing platform companies in life sciences. Comparable as a deep-science life sciences investor building companies around proprietary platforms addressing large therapeutic opportunities.
• Panacea Venture: Cross-border venture firm focused on emerging medical technologies and biotech, with strong US-China presence. Directly comparable as a co-investor alongside ETP in HLI's Series B and as a similarly structured life sciences firm bridging US and China markets.
• TVM Capital Healthcare: Healthcare-dedicated growth and venture firm with MENA and global mandates, lead investor in HLI's recent $39.8M Series B. Comparable as a sector-specialist healthcare investor with cross-border deal execution.

Broad incumbents

• Andreessen Horowitz Bio / a16z Bio + Health: Large multi-stage venture firm with a dedicated Bio + Health practice investing across therapeutics, digital health, and biotech. Comparable as a life sciences investor, but operates within a broader generalist tech platform rather than as a specialist.
• New Enterprise Associates (NEA): Large multi-stage venture firm with active healthcare and life sciences practice. Comparable because of its life sciences investing, though it operates across technology, consumer, and healthcare as a broad incumbent.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments25 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Emerging Technology Partners